Daunorubicin (Conventional)

Conventional Formulation

Cardiac, Myelosuppression; Extravasation Risk

  • Avoid Extravasation:  severe local tissue necrosis will occur.
  • Intravenous infusion use only. Never administer via IM or SC route. 
  • Cardiotoxicity:  Cumulative dose related. Potentially fatal CHF may occur months to years after completion of therapy.
  • Myelosuppression: severe form may occur with therapeutic doses; this may lead to hemorrhage or infection
  • Reduced dose in hepatic/renal dysfunction
  • Cardiotoxicity cumulative dose related. Incidence of myocardial toxicity increases after a total cumulative dose > 400 to 550 mg/m2 in adults, >300 mg/m2 in children older than 2 yrs, and > 10 mg/kg in children less than 2 yrs.
  • Experienced Physician in Equipped Facility

Monitoring data

  • Careful hematological monitoring
  • Evaluate EKG and systolic ejection fraction at baseline and before each course. A > 30% decrease in limb lead QRS associated with increased risk of cardiomyopathy.
  • Cardiotoxicity cumulative dose related. Incidence of myocardial toxicity increases after a total cumulative dose > 400 to 550 mg/m2 in adults, >300 mg/m2 in children older than 2 yrs, and > 10 mg/kg in children less than 2 yrs.
  • Increased risk associated with cardiac region radiation.
  • Evaluate hepatic/renal function prior to initiation of therapy.

Package inserts

Daunorubicin

Additional information

Keywords: xx
Updated: October 2016